Additional studies have shown a utility for using ibrutinib in AML with FLT3-ITD, NPM1, and DNMT3A mutations (50) as well as using JAK1/2 kinase inhibitor ruxolitinib plus venetoclax or with BET inhibitors (51, 52). Here, JAK1 is linked to acute myeloid leukemia.